PROTECTIVE ROLE OF RUTIN ON PACLITAXEL-INDUCED LIPID PEROXIDATION

Supratim Ray*

Department of Pharmaceutical Sciences, Assam University, Silchar 788011.

*Author for Correspondence: Supratim Ray

Department of Pharmaceutical Sciences, Assam University, Silchar 788011.

ABSTRACT
Considering drug induced lipid peroxidation as a possible mediator of drug induced toxicity and exploiting the free radical scavenging activity of antioxidant, the present study was designed to evaluate the free radical scavenging activity rutin on paclitaxel-induced lipid peroxidation. This *in vitro* work was carried out with goat liver as lipid source using malondialdehyde and 4-hydroxy-2-nonenal as model markers. The findings suggest that paclitaxel could induce lipid peroxidation to a significant extent and it was also found that rutin has the ability to suppress the paclitaxel-induced toxicity.

KEYWORDS: Paclitaxel, rutin, lipid peroxidation, malondialdehyde, 4-hydroxy-2-nonenal.

INTRODUCTION
Free radicals are highly reactive molecules with odd number of electrons. They are constantly being generated in the body and also being removed by endogenous antioxidant defense mechanism. Lipid peroxidation is a free radical related process that may occur in the biological system under enzymatic control or non-enzymatically.[1-3] The cytotoxic end products of lipid peroxidation are mainly aldehydes as exemplified by malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) etc.[4] Paclitaxel is one of the popular drugs in breast cancers in women of developed and developing countries. However the drug produces several side effects due to production of free radicals in the body.[5] It is reported that paclitaxel in combination with antioxidant reduces the drug induced lipid peroxidation.[6]

In view of the above findings and the ongoing search of the present author for antioxidant that may reduce drug induced lipid peroxidation[7-8] the present work has been carried out *in vitro* to evaluate the antiperoxidative potential of rutin on paclitaxel-induced lipid peroxidation.

MATERIALS
Thiobarbituric acid (TBA) and trichloroacetic acid (TCA) were purchased from Ranbaxy Fine Chemicals Ltd., New Delhi. 1,1,3,3, tetraethoxypropane was from Sigma chemicals Co. St. Louis, MO, USA. 2, 4-Dinitrophenylhydrazine (DNPH) was procured from SD Fine Chem. Ltd., Mumbai. The standard sample of 4-HNE was purchased from ICN Biomedicals Inc., Aurora, Ohio. Rutin was obtained from CDH Pvt. Ltd., New Delhi. Pure sample of paclitaxel used in present study was provided by United Biotech (P) Ltd., New Delhi, India. All other reagents were of analytical grade. Goat liver was used as the lipid source.

METHODS
Preparation of tissue homogenate
Goat liver was collected from Silchar Municipal Corporation approved outlet. Goat liver was selected because of its easy availability and close similarity with human liver in its lipid profile.[9] Goat liver perfused with normal saline through hepatic portal vein was harvested and its lobes were briefly dried between filter papers to remove excess blood and thin cut with a heavy-duty blade.

The small pieces were then transferred in a sterile vessel containing phosphate buffer (pH 7.4) solution. After draining the buffer solution as completely as possible, the liver was immediately grinded to make a tissue homogenate (1 g/ml) using freshly prepared phosphate buffer (pH 7.4). The homogenate was divided into four equal parts, which were then treated differently as mentioned below.

One portion of the homogenate was kept as control (C) while a second portion was treated with the paclitaxel (D) at a concentration of 0.143μM/g tissue homogenate. The third portion was treated with both paclitaxel at a concentration 0.143μM/g tissue homogenate and rutin at a concentration of 0.1666 mg / g homogenate (DA) and the fourth portion was

treated only with rutin at a concentration of 0.1666 mg / g tissue homogenate (A). After paclitaxel and /or rutin treatment, the liver tissue homogenate samples were shaken for five hours and the malondialdehyde and 4-hydroxy-2-nonenal content of various portions were determined.

Estimation of malondialdehyde (MDA) level from tissue homogenate

The extent of lipid peroxidation was measured in terms of malondialdehyde (MDA) content using thiobarbuturic acid (TBA) method.[10] The estimation was done at 5 hours of incubation and repeated in three animal sets. In each case three samples of 2.5 ml of incubation mixture were treated with 2.5 ml of 10% (w/v) trichloroacetic acid (TCA) and centrifuged at room temperature at 3000 rpm for 30 minutes to precipitate protein. Then 2.5 ml of the supernatant was treated with 5 ml of 0.002 (M) TBA solutions and then volume was made up to 10 ml with distilled water. The mixture was heated on a boiling water bath for 30 minutes.

Then tubes were cooled to a room temperature and the absorbance was measured at 530 nm against a TBA blank (prepared from 5 ml of TBA solution and 5 ml of distilled water) using Shimadju UV-1700 double beam spectrophotometer. The concentrations of MDA were determined from standard curve, which was constructed as follows. Different aliquots from standard 1, 1, 3, 3-tetrahydroxypropane (TEP) solution were taken in graduated stoppered test tubes and volume of each solution was made up to 5 ml. To each solution, 5 ml of TBA solution was added and the mixture was heated in a steam bath for 30 minutes. The solutions were cooled to a room temperature and their absorbances were measured at 530 nm against TBA as blank. By plotting absorbances against concentrations a straight line passing through the origin of grid was obtained. The best-fit equation is $A = 0.007086M$, where M= nanomoles of MDA, A= absorbance, r = 0.995, SEE= 0.006.

Estimation of 4-hydroxy-2-nonenal (4-HNE) level in tissue homogenate

The estimation was done at 5 hours of incubation and repeated in three animal sets. In each case three samples of 2 ml of incubation mixture was treated with 1.5 ml of 10% (w/v) TCA solution then centrifuged at 3000 rpm for 30 min. 2 ml of the filtrate was treated with 1 ml of 2, 4-dinitrophenyl hydrazine (DNPH) (100 mg / 100 ml of 0.5 M HCl) and kept for 1 hour at room temperature.

After that, the samples were extracted with hexane, and the extract was evaporated to dryness under argon at 40^0 C. After cooling to a room temperature, 2 ml of methanol was added to each sample and the absorbance was measured at 350 nm against methanol as blank[11] using Shimadju UV-1700 double beam

spectrophotometer. The values were determined from the standard curve. The standard calibration curve was drawn based on the following procedure. A series of dilutions of 4-HNE in different concentrations of solvent (phosphate buffer) were prepared. From each solution 2 ml of sample pipette out and transferred into stoppered glass tube. 1 ml of DNPH solution was added to all the samples and kept at room temperature for 1 hour. Each sample was extracted with 2 ml of hexane for three times. All extracts were collected in stoppered test tubes. After that extract was evaporated to dryness under argon at 40^0C and the residue was reconstituted in 1 ml of methanol. The absorbance was measured at 350 nm using the 0 μM standard as blank. The best-fit equation is: Nanomoles of 4-HNE = $(A_{350} - 0.005603185) / 0.003262215$, where A_{350} = absorbance at 350nm, r = 0.999, SEM = 0.007

STATISTICAL ANALYSIS

Analysis of variance (ANOVA) and multiple comparison analysis using least significant different procedure[12-13] were also performed on the percent changes data of various groups such as paclitaxel-treated (D), paclitaxel and rutin (DA) and only rutin-treated (A) with respect to control group of corresponding time.

RESULTS AND DISCUSSION

The percent changes in MDA and 4-HNE content of different samples at 5 hours of incubation were calculated with respect to the control of the corresponding time of incubation and was considered as indicator of the extent of lipid peroxidation.

From Figure 1 it was evident that tissue homogenates treated with paclitaxel showed an increase in MDA (36.14 %) content in samples with respect to control at 5 hours of incubation to a significant extent. The observations suggest that paclitaxel could significantly induce the lipid peroxidation process. MDA is a highly reactive three-carbon dialdehyde produced as a byproduct of polyunsaturated fatty acid peroxidation and arachidonic acid metabolism.[14]

But the MDA (10.09 %) content were significantly reduced in comparison to paclitaxel-treated group when tissue homogenates were treated with paclitaxel in combination with rutin. Again the tissue homogenates were treated only with the rutin then the MDA (8.19%) level were reduced in comparison to paclitaxel treated group. This decrease may be due to the free radical scavenging property of the rutin. So the decrease in MDA content of samples, when treated with paclitaxel and rutin implies the free radical scavenging property of rutin.

Figure 1: Effects of rutin on paclitaxel-induced changes in MDA content (n=3); D, DA & A indicate only paclitaxel-treated, paclitaxel & rutin -treated and only rutin –treated samples

It was also evident from Figure 2 that tissue homogenates treated with paclitaxel showed an increase in 4-HNE (9.56%) content in samples with respect to control to a significant extent. The observations suggest that paclitaxel could significantly induce the lipid peroxidation process. 4-HNE is formed due to lipid peroxidation occurring during episodes of oxidant stress, readily forms adducts with cellular proteins; these adducts can be assessed as a marker of oxidant stress in the form of lipid peroxidation.[15] But the 4-HNE content was significantly reduced (-5.27%) in comparison to control and paclitaxel-treated group when tissue homogenates were treated with paclitaxel in combination with rutin. 4-HNE as well as related aldehydes display strong cytotoxicity and their effective removal could play an important role in a broad defense system of the liver *in vivo* against damaging effects of lipid peroxidation.[16] Again the tissue homogenates was treated only with rutin then the 4-HNE level was reduced (-4.28%) in comparison

to the control and the paclitaxel treated group. This decrease may be explained by the free radical scavenging property of the rutin.


Figure 2: Effects of rutin on paclitaxel-induced changes in 4-HNE content (n=3); D, DA & A indicate only paclitaxel-treated, paclitaxel & rutin -treated and only rutin –treated samples.

To compare means of more than two samples, multiple comparison analysis along with analysis of variance was performed on the percent changes data with respect to control of corresponding hours. It is seen that there is significant differences among various groups (F1) such as paclitaxel-treated, paclitaxel and rutin-treated and only rutin-treated. But within a particular group, differences (F2) are insignificant which shows that there is no statistical difference in animals in a particular group (Tables 1). The Tables also indicate that the level of MDA / 4-HNE in all three groups i.e. paclitaxel–treated, paclitaxel and rutin-treated and only rutin-treated groups are statistically significantly different from each other.

Table 1: ANOVA & Multiple comparison for changes of MDA and 4-HNE content

Name of the antioxidant	Marker of lipid peroxidation	Analysis of variance and multiple comparison
Rutin	MDA	F1=129128.2[df=(2,4)], F2=0.711[df=(2,4)], Pooled variance $(S^2)^*$=0.0056, Critical difference $(p=0.05)^{\#}$ LSD=0.141 Ranked means** (D) (DA) (A)
	4-HNE	F1=18075.8 [df=(2,4)], F2=0.196[df=(2,4)], Pooled variance $(S^2)^*$=0.011, Critical difference $(p=0.05)^{\#}$ LSD=0.197 Ranked means** (D) (DA) (A)

Theoretical values of F: p=0.05 level F1=6.94 [df=(2,4)], F2=6.94 [df=(2, 4)] F1 and F2 corresponding to variance ratio between groups and within groups respectively; D, DA & A indicate only paclitaxel-treated, paclitaxel & rutin -treated and only rutin –treated samples * Error mean square, # Critical difference according to least significant procedure (LSD) **Two means not included

within same parenthesis are statistically significantly different at p=0.05 level.

CONCLUSION
The data presented in this work showed the lipid peroxidation induction potential of paclitaxel, which may be related to its toxic potential. The results also suggest

the antiperoxidative effects of rutin and demonstrate its potential to reduce paclitaxel induced toxic effects.

REFERENCES

1. Gutteridge, JMC, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Aca Sci., 2000; 899: 136-47.
2. Stohs SJ. The role of free radicals in toxicity and disease. J Basic Clin Physiol Pharmacol., 1995; 6: 205-28.
3. Romero RJ, BoschMorell F, Romero MJ, Jareno EJ, Romero B, Marin N, Roma J. Lipid peroxidation products and antioxidants in human disease. Environ Health Perspect., 1998; 106: 1229-34.
4. Esterbauer H, Zollner H, Schauer RJ. Hydroalkenals: Cytotoxic products of lipid peroxidation. Biochem Mol Biol., 1998; 1: 311-19.
5. Campos FC, Victorino VJ, Martins-Pinge MC, Cecchini AL, Panis C, Cecchini R. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. Food Chem Toxicol., 2014; 68:78-86.
6. Padmavathi R, Senthilnathan P, Chodon D, Sakthisekaran D. Therapeutic effect of paclitaxel and propolis on lipid peroxidation and antioxidant system in 7,12 dimethyl benz(a)anthracene-induced breast cancer in female Sprague Dawley rats. Life Sci., 2006; 78: 2820-5.
7. Ray S, Roy K, Sengupta C. Evaluation of protective effects of water extract of *Spirulina platensis* (blue green algae) on Cisplatin-induced lipid peroxidation. Indian J Pharm Sci., 2007; 69: 378-83.
8. Ray S, Roy K, Sengupta C. Exploring the protective effect of ascorbic acid and water extract of *Spirulina platensis* (blue green algae) on methotrexate-induced lipid peroxidation. Iranian J Pharm Sci., 2007; 3: 217-28.
9. Hilditch TP, Williams PN. The Chemical Constituents of Fats. London: Chapman & Hall; 1964.
10. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxidation in animal tissue by thiobarbituric acid reaction. Anal Biochem., 1979; 95: 351-58.
11. Kinter M. Free Radicals- A Practical Approach. Oxford, Oxford University Press., 1996; 133-45.
12. Snedecor GW, Cochran WG. Statistical Methods. New Delhi: Oxford & IBH Publishing Co Pvt Ltd., 1967.
13. Bolton S. Statistics. In: Gennaro AR, editor. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott Williams & Wilkins., 2000; 124-58.
14. Yahya MD, Pinnsa JL, Meinke GC, Lung CC. Antibodies against malondialdehyde (MDA) in MLR / lpr / lpr Mice: Evidence for an autoimmune mechanism involving lipid peroxidation. J Autoimmun., 1996; 9: 3-9.
15. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related articles. Free Radic Biol Med., 1991; 11: 81-128.
16. Esterbauer H, Zollner H, Lang J. Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. Biochem J., 1985; 228: 363-73.